Our community narratives are driven by numbers and valuation.
With a 44% profit margin and a PE ratio of half its Energy sector peers of only 7.2X, Pulse Seismic is projecting revenues to grow just under 14% per year. Pulse has an outstanding track record, model balance sheet and pays a dividend.Read more
Gold exploration project in Canada, Timmins camp. Current PEA was done in 2022 - 11y mine life, NPV 387M with 33% IRR @1700 gold.Read more
AYA is a de-risked production story with exceptional silver torque trading at a Morocco discount. The company has proven operational competence (rare in junior/mid-tier mining), operates one of the highest-grade primary silver mines globally, and offers 5-10x potential upside if the silver bull thesis plays out.Read more

A 5-Year stock price analysis for IMPACT Silver Corp (TSXV:IPT) in a monetary metals bull market + an equity crash scenario similar to post 1999. As of November 28, 2025, IPT trades at ~CA$0.28 (~$0.20 USD) with a $66M USD market cap and 323.73M shares outstanding, post-$16M financing.Read more

Key Assumptions: Resource Totals (2023 Updated Resource): Gold: 700,000 oz (Lomero-Poyatos). Silver: 7 million oz (Lomero-Poyatos).Read more

Asante Gold – Updated Snapshot (Sept 2025) Latest official guidance and disclosures Five-year outlook: company targets ~500,000 oz/yr by 2028 and >US$2B cumulative unlevered FCF (company outlook). asantegold.com+1 2026 production target (company): ~450,000 oz consolidated (Bibiani + Chirano).Read more

Revenue of 10% is the analysts assumption and is reasonable considering increased government spending and the backlogs of their existing contracts. It is also in line with their growth over the past two years.Read more
(Updated October 2025) 1. Business Summary TMX Group is the backbone of Canada’s financial markets.Read more
Cybin’s aggressive analyst price targets make sense when you view the company through a true late-stage biotech lens rather than a speculative psychedelic stock. With more than US$225 million in cash after retiring all debt, Cybin is now one of the only fully funded companies in the entire sector with enough runway to complete multiple Phase 3 trials and deliver two major clinical readouts—Phase 2 CYB004 data in Q1 2026 and pivotal Phase 3 CYB003 results in Q4 2026.Read more